In Re Accuray, Inc. Shareholder Derivative Litigation

757 F. Supp. 2d 919, 2010 U.S. Dist. LEXIS 90068, 2010 WL 3447615
CourtDistrict Court, N.D. California
DecidedAugust 31, 2010
Docket09-05580 CW
StatusPublished
Cited by12 cases

This text of 757 F. Supp. 2d 919 (In Re Accuray, Inc. Shareholder Derivative Litigation) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Accuray, Inc. Shareholder Derivative Litigation, 757 F. Supp. 2d 919, 2010 U.S. Dist. LEXIS 90068, 2010 WL 3447615 (N.D. Cal. 2010).

Opinion

ORDER GRANTING DEFENDANTS’ MOTION TO DISMISS

CLAUDIA WILKEN, District Judge.

Defendants Euan S. Thomson, Wayne Wu, Li Yu, Robert S. Weiss, Elizabeth Dávila, John P. Wareham, Robert E. McNamara, John R. Adler, Jr. and nominal Defendant Accuray Incorporated move to dismiss this shareholder derivative complaint. Derivative Plaintiffs Thomas Beebe, Sanjayh Israni, Eric Bachinski and Christopher Borrelli oppose the motion. The matter was heard on August 12, 2010. Having considered all of the papers filed by the parties and oral argument on the motion, the Court GRANTS Defendants’ motion to dismiss and grants leave to amend.

BACKGROUND

Plaintiffs are shareholders of nominal Defendant Accuray. Plaintiffs bring this shareholder derivative suit against eight of Accuray’s directors. Accuray designs, develops and sells the CyberKnife, an image-guided robotic radiosurgery system designed to treat solid tumors. The CyberKnife is Accuray’s sole product.

Defendant Thomson is Accuray’s Chief Executive Officer and has been on the Board of Directors since March, 2002. *923 Defendant McNamara was Accuray’s Senior Vice President and Chief Financial Officer from December, 2004 until his resignation on September 11, 2008. Defendant Wu is Accuray’s Chairman of the Board and has been a Director since April, 1998. Defendant Yu is the Chairman of the Compensation Committee, a member of the Audit Committee and has been a Director since June, 2004. Defendant Weiss is the Chairman of the Audit Committee and has been a Director since January, 2007. Defendant Dávila is the Vice Chairman of the Board, a member of the Audit Committee and Compensation Committee, and has been a Director since February, 2008. Defendant Wareham was a Director from February, 2008 until his resignation on January 7, 2010. Defendant Tu was a Director from May, 2004 to November, 2008. Defendant Adler was a founder of Accuray and was a Director from December, 1990 to July, 2009.

Plaintiffs allege that Defendants made material misrepresentations about Accuray’s revenues and, specifically, about Accuray’s backlog. On February 7, 2007, the day Accuray initiated the initial public offering (IPO), it defined backlog as “deferred revenue and future payments that our customers are contractually committed to make, but which we have not yet received. Backlog includes contractual commitments from CyberKnife system purchase agreements, service plans and minimum payment requirements associated with our shared ownership programs.” Accuray’s registration statement, which accompanied the IPO and was filed with the SEC, included several disclosures detailing the risk related to the business. For instance, Accuray stated:

Because of the high unit price of the CyberKnife system, and the relatively small number of units installed each quarter, each installation of a CyberKnife system can represent a significant component of our revenue for a particular quarter. Therefore, if we do not install a CyberKnife system when anticipated, our operating results may vary significantly and our stock price may be materially harmed.
Events beyond our control may delay installation and the satisfaction of contingencies required to receive cash inflows and recognize revenue, such as ... customer funding or financing delay .... Therefore, delays in the installation of CyberKnife systems or customer cancellations would adversely affect our cash flows and revenue, which would harm our results or operations and could cause our stock price to decline.
If third-party payors do not continue to provide sufficient coverage and reimbursement to healthcare providers for use of the CyberKnife system, our revenue would be adversely affected.

Request for Judicial Notice (RJN), 1 Ex. A at 12-13 (Comp., Ex. 1 at 12-13). Accuray further noted that it “may be unable to convert all of this backlog into recognized revenue due to factors outside our control.” Id. at 44 (Id. at 44). These disclosures were included in Accuray’s quarterly and annual filings throughout the time period during which Plaintiffs allege Defendants’ wrongdoing.

In a May 1, 2007 press release, Accuray announced that as of March 31, 2007, it had changed its definition of backlog. The new definition included “signed non-contingent contracts as well as backlog under signed contingent contracts that the Com *924 pany believes have a substantially high probability of being booked as revenue.” Comp. ¶ 69 (Comp. ¶ 61). Accuray stated, “Contingencies under customer contracts included in backlog include customer acceptance of the Company’s legal terms and conditions of sale, hospital board approvals, customer establishment of necessary financing or legal entities and, in U.S. states, governmental approval of a certificate of need (CON) for the operation of a radiosurgery system.” Id. (Comp., Ex. 5).

Also on May 1, 2007, Thomson and McNamara held an earnings conference call to discuss the third fiscal quarter of 2007. In that call, Thomson stated, “On balance, we feel confident that 90% of the total backlog reported will be converted to revenue.” Id. ¶ 80 (Comp., Ex. 6 at 5). He also noted that the “total backlog reported this quarter, taken in conjunction with reported revenue, is a good and reliable indicator that [sic] the new business generated during a given quarter.” Id. (Comp., Ex. 6 at 5). McNamara also expressed “confidence that at least 90% of the quoted backlog will convert to revenue.” Id. ¶ 81. (Comp., Ex. 6 at 8). He also stated, “We believe that our current definition of backlog is a more meaningful metric for Accuray as an indicator of future revenue.” Id. (Comp., Ex. 6 at 8). He also noted, “On a quarterly basis, the company will review each contingent contract to determine whether progress towards satisfaction of contingencies is sufficient to support inclusion of the contract within the backlog.” Id. (Comp., Ex. 6 at 8). Accuray announced increased revenues and backlogs throughout the rest of fiscal year 2007.

Plaintiffs allege that these statements were false when made because the revised backlog definition was not a better metric than the previous backlog definition and that Defendants knew that they would not realize 90% of the new backlog definition. Plaintiffs specifically claim that the backlog included risky contingent contracts that did not have a substantial likelihood of resulting in future revenue and orders that had little chance of becoming finalized CyberKnife installations. Plaintiffs also allege that cancelled orders were not timely removed from the backlog figures.

On August 30, 2007, Directors Thomson, Wu, Yu, Weiss, Tu and Adler authorized the repurchase of $25 million of Accuray shares. Over the course of the next year, Accuray repurchased $23.9 million of its own stock. Plaintiffs claim that these Defendants, as well as Dávila and Wareham, who were later appointed to the Board, consciously disregarded their fiduciary duties when they allowed this stock to be repurchased. Plaintiffs allege that the stock was trading at an artificially inflated price due to the false and misleading statements made by Defendants.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Biefeldt v. Wilson
2022 IL App (1st) 210336 (Appellate Court of Illinois, 2022)
In re Bofi Holding, Inc.
382 F. Supp. 3d 992 (S.D. California, 2019)
In re Facebook, Inc.
367 F. Supp. 3d 1108 (N.D. California, 2019)
In re Fitbit, Inc. Stockholder Derivative Litigation
Court of Chancery of Delaware, 2018
In re Yahoo! Inc. Shareholder Derivative Litigation
153 F. Supp. 3d 1107 (N.D. California, 2016)
Levine v. Liveris
216 F. Supp. 3d 794 (E.D. Michigan, 2016)
Iron Workers Mid-South Pension Fund v. Davis
93 F. Supp. 3d 1092 (D. Minnesota, 2015)
In re Galena Biopharma, Inc.
83 F. Supp. 3d 1047 (D. Oregon, 2015)
In re Polycom, Inc.
78 F. Supp. 3d 1006 (N.D. California, 2015)
In re Facebook, Inc.
922 F. Supp. 2d 445 (S.D. New York, 2013)
Freuler v. Parker
803 F. Supp. 2d 630 (S.D. Texas, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
757 F. Supp. 2d 919, 2010 U.S. Dist. LEXIS 90068, 2010 WL 3447615, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-accuray-inc-shareholder-derivative-litigation-cand-2010.